U.S. market Closed. Opens in 1 day 3 hours 41 minutes

TARS | Tarsus Pharmaceuticals, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Revenue17.45M25.82M57.03MN/AN/AN/A
Cost of Revenue1.59M955.00K2.08M246.00K74.00K1.00K
Gross Profit15.85M24.86M54.95M-246.00K-74.00K-1.00K
Operating Expenses159.01M87.57M67.11M27.00M4.30M1.35M
Selling, General & Admin108.70M44.95M25.40M8.17M1.14M449.00K
Research & Development50.31M42.62M41.71M18.83M3.16M901.00K
Other Operating ExpensesN/A86.00K-73.00KN/AN/AN/A
Operating Income-143.16M-62.71M-12.16M-27.00M-4.30M-1.35M
Other Expenses / Income7.26M617.00K-1.61M188.00K-371.00K32.00K
Before Tax Income-135.89M-62.09M-13.77M-26.81M-4.67M-1.32M
Income Tax ExpensesN/A-4.00K55.00K1.00K1.00K1.00K
Net Income-135.89M-62.09M-13.83M-26.81M-4.67M-1.32M
Interest Expenses3.35M2.20MN/A188.00K40.00KN/A
Basic Shares Outstanding29.38M24.62M20.55M20.32M19.51M4.29M
Diluted Shares Outstanding29.38M24.62M20.55M20.32M19.51M4.29M
EBITDA-131.67M-59.11M-13.17M-26.56M-4.55M-1.35M
EBITDA Margin-754.69%-228.95%-23.09%0.00%0.00%0.00%
EBIT-132.55M-59.90M-13.77M-26.62M-4.63M-1.32M
EBIT Margin-759.71%-232.01%-24.15%0.00%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙